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Abstract 
 
 
Objective: Hypercoagulability is a commonly described complication in patients with 
Cushing's syndrome. Recent clinical studies have indicated various abnormalities of 
coagulation and fibrinolysis parameters which may be related to that phenomenon. The aim of 
this study was to investigate the mechanisms underlying the hypercoagulable state in patients 
with Cushing's syndrome.  
Research methods and procedures: A wide range of serum markers involved in the processes 
of blood coagulation and fibrinolysis was measured in a group of 33 patients with Cushing's 
syndrome and 31 healthy controls. No participant was taking medication which could 
influence the result or had known diseases, except hypertension and diabetes, which could 
affect blood coagulation or fibrinolysis parameters. 
 Results:  Patients with Cushing's syndrome had higher levels of clotting factors II (P=0.003), 
V (P<0.001), VIII (P<0.001), IX (P<0.001), XI (P<0.001) and XII (P=0.019), protein C 
(P<0.001), protein S (P<0.001), C1-inhibitor (P<0.001) and PAI-1 (P=0.004). The activity of 
fibrinolytic markers, plasminogen (P<0.001), antithrombin (P<0.001) and antithrombin 
antigen (P=0.001) was also increased in the patient group.  
Conclusion: The study has demonstrated hypercoagulability in patients with Cushing's 
syndrome manifest as increased prothrombotic activity and compensatory activation of the 
fibrinolytic system. We propose the introduction of thromboprophylaxis in the preoperative 
and early postoperative periods, combined with  a close follow-up in order to prevent possible 
thromboembolic events in patients with Cushing's syndrome.  
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Introduction 
 
Hypercoagulability is a commonly described  complication in patients with Cushing's 
syndrome. Thromboembolic events have been reported both in patients with endogenous 
cortisol hypersecretion and in those treated with glucocorticoids (1-6). However, the 
pathogenesis of the thrombotic tendency in these patients has not been appropriately 
explained. In vitro studies have demonstrated a lower fibrinolytic activity induced by 
corticosteroids due to the stimulated release of the plasminogen activator inhibitor type 1 
(PAI-1) or to the suppression of plasminogen activator secretion (7-9). A study on a canine 
model reported an increase of  the thrombin-antithrombin complex (10). 
Recent clinical studies have indicated various abnormalities of different coagulation 
and fibrinolysis parameters which may be responsible for the increased risk of 
thromboembolism in patients with hypercortisolism (11-15). Increased levels of serum factor 
VIII, von Willebrand factor (vWF), plasminogen, tissue plasminogen activator (t-PA) antigen 
and PAI-1 activity has been observed in the patients with Cushing’s syndrome as compared to 
healthy controls (11-13). Conversely, in another study patients with Cushing's syndrome had 
mean PAI-1, t-PA and vWF-Ag levels insignificantly different from those found in the 
controls (15). Similarly, a study by Fatti et al. disclosed no significant difference in the PAI-1 
level between patients with Cushing's syndrome and controls (16).     
Since data from different studies are inconsistent, the issue of hypercoagulability in 
patients with Cushing's syndrome remains to be reassessed. Accordingly, the aim of this study 
was to provide an additional contribution to existing knowledge and, possibly, an additional 
explanation on the mechanisms underlying hypercoagulability in patients with Cushing's 
syndrome through the analysis of the wide range of markers involved in the processes of 
blood coagulation and fibrinolysis.  
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Results 
 
The haemostatic and fibrinolytic markers in patients and control subjects are 
summarized in Table 2. Alteration of at least two parameters was demonstrated in all patients 
with Cushing's syndrome. In 25 patients (75.8%) alteration was detected in 5 or more 
haemostatic and fibrinolytic parameters    
As compared with the controls, serum levels of coagulation factors II (P = 0.003), V 
(P < 0.001), VIII (P < 0.001), IX (P < 0.001), XI (P < 0.001) and XII (P = 0.019) were 
significantly higher in patients with Cushing's syndrome. Similarly, protein C (P < 0.001), 
protein S (P < 0.001), antithrombin (P < 0.001), anthitrombin Ag (P = 0.001), C1 inhibitor (P 
< 0.001), plasminogen (P <0.001) and PAI-1 (P = 0.004) levels were also significantly higher 
in patients with Cushing's syndrome. Factor VII and fibrinogen levels were not significantly 
different from the controls. Patients with Cushing's syndrome had a significant shortening of 
APTT (P <0.001) whereas no differences were noted for PT and TT.  
The amount of daily urine cortisol excretion in patients with Cushing's syndrome was 
positively correlated with antithrombin activity (r=0.46; P=0.01) and FVII level (r=0.36; 
P<0.05). In the comparison of patients with ACTH dependent and ACTH non-dependent 
Cushing’s syndrome no significant differences in the level of coagulation parameters were 
noted.  
The analysis of coagulation and fibrinolytic markers in patients with Cushing's 
syndrome and in the presence of diabetes, hypertension and a high BMI revealed no 
differences either between hypertensive and non-hypertensive, or diabetic and non-diabetic 
patients. With respect to BMI, patients with BMI  30 as compared to those with BMI < 30 
showed  significantly higher C1-inhibitor (P = 0.04) and factor II  levels (P = 0.03).   
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Discussion     
 
It is well known that patients with Cushing's syndrome are at an increased risk of 
thromboembolism (17), which can be explained by an increased level of procoagulation 
factors, reduced levels of fibrinolytic factors, or both. This impairment in the coagulation 
process may also contribute to the development of atherosclerosis (18) and subsequent 
cardiovascular morbidity and mortality (19, 20). However, the exact mechanism of the 
prothrombotic state associated with hypercortisolism is still not fully understood.  
Some studies focused on coagulation and fibrinolysis parameters in patients with 
Cushing's syndrome, each reporting a number of abnormalities. Increased levels of PAI-I, t-
PA, vWF-Ag, II, V, VIII, IX, XIII clotting factors, and depletion of antithrombin-III have 
been reported (4, 11-13). In a small series of patients with the active disease Fatti et al. 
observed significantly increased vWF-Ag, thrombin-antithrombin complex and plasmin-
antiplasmin complex levels (16). They suggested that the prothrombotic state is related to an 
enhanced metabolic function of endothelial cells. In the same study, the PAI level, although 
higher, was not significantly different in active patients as compared to controls.  
The data presented in this  study suggest that patients with Cushing's syndrome display 
an increased risk of thromboembolism, determined by higher levels of clotting factors II 
(P=0.003), V (P<0.001), VIII (P<0.001), IX (P<0.001), XI (P<0.001) and XII (P=0.019), 
protein C (P<0.001), protein S (P<0.001), C1-inhibitor (P<0.001) and PAI-1 (P=0.004)  as 
compared to healthy controls. The possible underlying mechanism was cortisol-induced up-
regulation of mRNA transcription of various coagulation factors. The increased activity of 
fibrinolytic markers; plasminogen (P<0.001), antithrombin (P<0.001) and antithrombin 
antigen (P=0.001), was probably a secondary event due to the activation of coagulatiuon. 
Although we did detect some correlation between coagulation markers and urine free 
cortisol, these two parameters were not significantly associated. A similar finding has also 
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been demonstrated in previous reports (14, 15). To some extent, this could possibly be 
attributed to the day to day variability of urinary free cortisol excretion. Furthermore, 
coagulation levels and fibrinolysis parameters depend not only on the degree of 
hypercortisolism but also on the duration of the disease.  
It has recently been observed that patients with persistent hypercortisolism have a 
higher mortality rate during the first year after initial diagnosis (21) which can be attributed  
to thromboembolic events. A study by Boscaro et al. indicated that 10% of patients with 
Cushing's syndrome die due to thrombotic events (17). It has been observed that the early 
postoperative period is associated with a high thrombotic risk (11). Conversely, in another 
study involving 53 patients with Cushing's syndrome, six patients suffered deep venous 
thrombosis or pulmonary embolism. The authors of the study estimated that those 
thromboembolic episodes appeared as frequently as expected for patients undergoing any 
other major surgery (5). In our group, one patient had deep vein thrombosis, whereas two had 
an episode of pulmonary embolism during the disease. However, the values of thrombotic and 
fibrinolytic markers in those patients were not different when compared to patients without 
such events. Elevated concentrations of haemostatic and fibrinolytic markers present in all the 
patients who participated in the study can indicate a sub-clinical activation of the coagulation 
cascade without overt thromboembolic events. 
On the basis of these observations, the main dilemma seems to be whether these 
patients need peri- and postoperative thromboprophylaxis different from other patients 
undergoing major surgery. In view of this consideration, the major task would be a 
prospective study with patients' outcomes after the implementation of prophylactic 
anticoagulation as a primary endpoint. A recent study involving  a large group of patients with 
Cushing's syndrome indicated a huge reduction of morbidity and mortality due to 
thromboembolic events after the introduction of postoperative prophylactic anticoagulation 
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(17). In the study the patients were treated with warfarin (after a short-term postoperative 
heparin therapy) for at least four months. The treatment was discontinued when the cure of 
the disease and normalization of coagulation parameters were demonstrated. Therefore, the  
introduction of  pre- and postoperative thromboprophylaxis in patients with Cushing's 
syndrome appears to be reasonable.  
Considering the aetiology of hypercoagulability in patients with Cushing's syndrome 
we need to accept the possibility that hypercoagulation could be related to hypertension and 
diabetes per se. A higher vWF-Ag level has been found in hypertensive as compared to 
normotensive patients with Cushing's disease (16). In another study, a statistically significant 
difference in PAI-1 was found between diabetic and nondiabetic patients with 
hypercortisolemia (22). Furthermore, impairment of coagulation and fibrinolytic parameters 
could be associated with obesity (23). Finally, some patients with Cushing's syndrome 
presented clinically with polycythemia (24) which can also contribute to an increased risk of 
thromboembolism.  
In the present study, 25 patients (75.8%) had hypertension, 9 (27.3%) had type 2 
diabetes and 15 (45.5%) were obese. No significant differences in the activity of the analysed 
coagulation factors were found between patients with and without hypertension or diabetes. In 
contrast, BMI  30 was associated with significantly higher of C1-inhibitor and clotting factor 
II  levels.       
Several studies have recently showed that patients with clinically inapparent adrenal 
masses may present with clinical signs of a mild cortisol excess known as  subclinical 
Cushing's syndrome (25-27). Patients with a subclinical Cushing's syndrome are at an 
increased cardiovascular risk demonstrated by changes in carotid intimal-medial thickness 
(28). With respect to these data it would be of interest to analyse whether adrenal 
incidentaloma is associated with an increased risk of thromboembolism. The only study in 
 9
this field involving a small series of twelve patients with adrenal incidentaloma observed 
higher PAI-1, tPA and vWF-Ag levels (15).  
 In conclusion, the present study has demonstrated hypercoagulability in patients with 
Cushing's syndrome manifest as  increased prothrombotic activity and compensatory 
activation of the fibrinolytic system. Based on these data, in such patients we suggest the 
introduction of prophylactic anticoagulation in the preoperative and early postoperative 
periods.  
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Materials and methods 
 
 
Patients 
 
 
Our group comprised thirty-three consecutive patients (25 females, 8 males; mean age 
45.4±2.3 yr) with Cushing's syndrome in the active phase of the disease, and thirty-one age 
and sex matched healthy controls (19 females, 12 males; mean age 48.7±2.5 yr). The study 
was conducted in the Department of Endocrinology, University Hospital Zagreb, and 
approved by the local Ethics Committee. All the patients and controls were informed about 
the study protocol and gave their written consent.  
The clinical and demographic characteristics of patients with Cushing's syndrome and 
of the controls are shown in Table 1. No participant was taking drugs or had a disease, except 
hypertension and diabetes, which could affect blood coagulation or fibrinolysis parameters. 
The controls were recruited among hospital personnel and their friends. The diagnosis of 
Cushing's syndrome was based on characteristic clinical presentation and on the results of 
standard hormonal criteria (increased urinary free cortisol, absence of typical cortisol and 
ACTH diurnal rhythm, nonsuppressibility of cortisol secretion in the 1 mg overnight 
dexamethasone test and classic 2-days 2 mg dexamethasone test).  Additionally, the high-dose 
dexamethasone test and inferior petrosal sinus catheterisation with basal and CRH-stimulated 
blood sampling were run where indicated in order to verify the distinction between ectopic 
ACTH secretion and Cushing’s disease. Twenty-five patients (75.8%) had pituitary disease 
whereas eight (24.2%) had cortisol producing adrenal adenoma. Twenty-five patients (75.8%) 
had hypertension and 9 (27.3.6%) type 2 diabetes. Fifteen patients (45.5%) were obese (BMI 
 30). One patient (3.0%) had  deep vein thrombosis and 2 (6.0%) pulmonary embolism 
during the disease.  
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Laboratory  tests 
 
Venous blood was drawn from the participants and collected in glass tubes for 
determination of prothrombin time (PT), activated partial thromboplastin time (APTT), 
thrombin time (TT), fibrinogen, factors II, V, VII, VIII, IX, XI, XII, plasminogen, protein C 
and protein S activity, antithrombin, antithrombin antigen, C1-inhibitor and plasminogen 
activator inhibitor-1 (PAI-1). Prothrombin time was determined by Innovin reagents. 
Activated partial thromboplastin time was determined by Actin FS reagents (Siemens Medical 
Solutions Diagnostics /Deerfield, IL, USA/). Fibrinogen was quantified by the modified 
Clauss method (Siemens Medical Solutions Diagnostics /Deerfield, IL, USA/).  Standard one-
stage clotting assays using a specific factor deficient plasma as a substrate were used for the 
determination of factors II, V, VII, VIII, IX, XI, XII (Siemens Medical Solutions Diagnostics 
/Deerfield, IL, USA/). Antithrombin, protein C activity, protein C1-inhibitor, PAI, and 
plasminogen were quantified by chromogenic determination (Siemens Medical Solutions 
Diagnostics /Deerfield, IL, USA/). Protein S activity was quantified by the clotting assay 
(Siemens Medical Solutions Diagnostics /Deerfield, IL, USA/). The antithrombin antigen was 
quantified by nephalometric determination (Siemens Medical Solutions Diagnostics 
/Deerfield, IL, USA/).  
 
Statistics 
 
Statistical analysis was run by using SPSS 13.0 (SPSS, Chicago, USA), with 
significance set at P<0.05. Non-parametric statistical methods were used in the analysis – 
medians and ranges as central tendency indicators, and Mann-Whitney and Spearmans tests in 
hypothesis testing.  
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Table 1. Clinical and demographic characteristics of the patients with Cushing's 
syndrome and controls  
  
 Cushing’s 
(n=33) 
 
Controls 
(n=31) 
P value 
Age (years) 50 (38-60) 51 (22-83) NS 
Body weight (kg) 78 (77-88) 80 (58-100) NS 
Body height (cm) 158 (155-170) 170 (156-185) NS 
BMI (kg/m2) 32 (27-36) 28.0 (21-34) 0.04 
Male/female 8/25  12/19 NS 
Hypertension 
   (yes/no) 
25/8 
 
5/26 0.001 
Diabetes 
  (yes/no) 
9/24 
 
0/31 0.001 
Cigarette smoking   
      (yes/no) 
6/27 
 
5/26 
 
NS 
The results are medians (range) 
NS – not significant; BMI-body mass index 
 
 18
Table 2. Haemostatic and fibrinolytic markers in patients with Cushing's syndrome and 
controls  
  
 Cushings 
(n=33) 
 
Controls 
(n=31) 
P value 
fibrinogen (g/l) 
  (n.r. 1.8-4.1) 
3.8 (1.8-4.2) 2.8 (2.3-4.4) NS 
antithrombin (%) 
  (n.r. 75-125) 
115.6 (57.5-120.4) 99 (69-114) <0.001 
antithrombin Ag (g/l) 
  (n.r. 0.19-0.31) 
0.31 (0.20-0.33) 0.28 (0.19-0.35) 0.001 
F II:C (IU) 
  (n.r. 0.75-1.20) 
1.36 (0.94-1.51) 1.02 (0.84-1.27) 0.003 
F V:C (IU) 
  (n.r. 0.75-1.20) 
1.57 (1.33-1.67) 1.24 (0.65-1.80) <0.001 
F VII:C (IU) 
  (n.r. 0.70-1.20) 
0.97 (0.89-1.32) 1.07 (0.58-1.89) NS 
F VIII:C (IU)     
  (n.r. 0.60-1.80) 
2.92 (1.53-3.08) 1.17 (0.76-1.96) 
 
<0.001 
F IX:C (IU) 
  (n.r. 0.60-1.80) 
1.47 (1.14-2.26) 1.04 (0.71-1.57) <0.001 
F XI:C (IU) 
  (n.r. 0.75-1.20) 
1.31 (1.11-1.55) 0.94 (0.73-1.40) 
 
<0.001 
F XII:C (IU) 
  (n.r. 0.70-1.40) 
0.57 (0.43-1.14) 1.00 (0.48-1.27) 
 
0.019 
protein C  (%) 
  (n.r. 70-140) 
163.2 (93.7-169.6) 120 (88-198) <0.001 
protein S  (%) 
  (n.r. 48-120) 
105.1 (84.5-113) 79 (47-124) <0.001 
C1 inhibitor  (%) 
  (n.r. 70-130) 
129.6 (116.8-
162.6)  
112 (16-150) <0.001 
PAI-1 (U/ml) 
  (n.r. 0.3-3.5) 
7.02 (2.79-8.5) 3.6 (0.1-7.3) 0.004 
Plasminogen (%) 
  (n.r. 75-150) 
115.6 (93.9-132.8) 104 (11-137) <0.001 
PT  (ratio) 
   (n.r. 0.70-1.30) 
1.19 (0.81-1.29) 1.16 (0.93-1.49) NS 
APTT  (s) 
   (n.r. 24-33) 
25.2 (25.1-30.9) 27 (25-29) <0.001 
TT  (s) 
   (n.r. 16-21) 
18 (17.2-18.3) 19 (16-32) NS 
The results are medians (range) 
NS – not significant; PAI-1-plasminogen activator inhibitor type 1; PT-prothrombin time; 
APTT-activated partial thromboplastin time; TT-thrombin time 
 
